Safety and tolerability of MEDI-551 in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2015
This article has no abstract
Epistemonikos ID: 646a7d0adc50405e51d55f932af4617ddf332b42
First added on: Apr 30, 2026